FDA Grants Priority Review to Genentech’s Enspryng for Rare Neurological Disease MOGAD
Event summary
- FDA granted Priority Review for Genentech’s Enspryng (satralizumab) for MOGAD, a rare autoimmune disease with no approved treatments.
- The filing is based on positive Phase III METEOROID study results, showing a 68% reduction in relapse risk compared to placebo.
- FDA decision expected by January 10, 2027; EMA validation also received for European market.
- Enspryng is already approved for neuromyelitis optica spectrum disorder (NMOSD) in 90+ countries.
The big picture
Genentech’s Enspryng represents a strategic push into rare neurological diseases, leveraging its IL-6 inhibition technology. The Priority Review designation underscores the unmet need in MOGAD, where no approved treatments exist. Success here could expand Genentech’s footprint in autoimmune therapies, complementing its existing NMOSD franchise.
What we're watching
- Regulatory Momentum
- Whether the FDA and EMA approvals will accelerate Enspryng’s market penetration in rare neurological diseases.
- Commercial Strategy
- How Genentech plans to position Enspryng against existing treatments for NMOSD and potential future indications.
- Pipeline Expansion
- The pace at which Genentech advances Enspryng into other autoimmune and inflammatory diseases like AIE and TED.
Related topics